Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. The company is headquartered in Foxboro, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2018-07-18. The firm is engaged in developing a platform and pipeline that is focused on creating cellular medicines called Red Cell Therapeutics. The Company’s Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create selective and allogeneic cellular medicines for treating a range of diseases. Red Cell Therapeutics can also be used to kill tumors in cancer, regulate the immune system for the treatment of autoimmune diseases and treat a number of other types of illnesses. The Company’s subsidiary is Rubius Therapeutics Securities Corporation.

Industry: Biological Products, (No Diagnostic Substances) Peers: Ambrx Biopharma Cayman, Inc. Perspective Therapeutics Inc Cidara Therapeutics, Inc. Sellas Life Sciences Group Inc Galera Therapeutics Inc Oncternal Therapeutics, Inc. Scorpius Holdings, Inc. IN8bio Inc Mustang Bio Inc